NCT01507428 · OUTCOME
ΔSUVpeak Prediction of Overall Survival, Progression Free Survival, and Lung Cancer Cause-specific Survival (ECOG-ACRIN)
Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer · Source last updated 2026-04-21
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- percent change
- Interval / dispersion
- Standard Deviation
- Time frame
- Up to 5 years
What was measured
ΔSUVpeak will be measured as 100\* (SUVpeak Mid-treatment - SUVpeak baseline)/(SUVpeak baseline) All survival measures will be measured in days from registration up to 5 years.
Analysis population: As a predictive marker, relative SUVpeak is reported by survival status in each survival category. For example, Relative ΔSUVpeak is reported separately for the 38 participants who were alive at the 5 year milestone and for the 69 patients who were not.
Groups in this outcome
Both Arms
Patients undergo chemoradiotherapy as defined for the arm of the study to which they were randomized.
18F-Fluoromisonidazole: Undergo FMISO PET/CT prior to therapy for patients enrolling at institutions participating in the FMISO correlative study
Arm I (Standard Chemoradiotherapy)
Patients undergo standard radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FMISO-PET imaging at baseline
18F-Fluoromisonidazole: Undergo FMISO PET/CT prior to therapy for patients enrolling at institutions participating in the FMISO correlative study
Carboplatin: Given IV
External Beam Radiation Therapy: Undergo radiotherapy
Arm II (Experimental Chemoradiotherapy)
Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.
18F-Fluoromisonidazole: Participants enrolled at institutions participating in the FMISO correlative study undergo FMISO-PET prior to treatment
Carboplatin: Given IV
Computed Tomography: Undergo FDG PET/CT
Computed Tomography: Undergo FMISO PET/CT (Correlative studies)
Fludeoxyglucose F-18: Undergo FDG PET/CT
Image-Guided Adaptive Radiation Therapy: Undergo individualized adaptive radiotherapy
Laboratory Biomarker Analysis: Correlative studies
Paclitaxel: Given IV
Positron Emission Tomography: Undergo FDG PET/CT
Positron Emission Tomography: Undergo FMISO PET/CT (Correlative studies)
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Both Arms | 107 |
|---|
| Arm I (Standard Chemoradiotherapy) | 36 |
|---|
| Arm II (Experimental Chemoradiotherapy) | 71 |
|---|
Reported measurements
ΔSUVpeak (Alive)
Analysis denominator · Participants
| Group | Source count |
|---|
| Both Arms | 38 |
|---|
| Arm I (Standard Chemoradiotherapy) | 14 |
|---|
| Arm II (Experimental Chemoradiotherapy) | 24 |
|---|
Values in percent change · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Both Arms | -34.71 | 53.23 | Not reported | Not reported | Not reported |
|---|
| Arm I (Standard Chemoradiotherapy) | -44.13 | 27.07 | Not reported | Not reported | Not reported |
|---|
| Arm II (Experimental Chemoradiotherapy) | -29.21 | 63.71 | Not reported | Not reported | Not reported |
|---|
ΔSUVpeak (Deceased)
Analysis denominator · Participants
| Group | Source count |
|---|
| Both Arms | 69 |
|---|
| Arm I (Standard Chemoradiotherapy) | 22 |
|---|
| Arm II (Experimental Chemoradiotherapy) | 47 |
|---|
Values in percent change · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Both Arms | -42.62 | 27.37 | Not reported | Not reported | Not reported |
|---|
| Arm I (Standard Chemoradiotherapy) | -34.43 | 34.13 | Not reported | Not reported | Not reported |
|---|
| Arm II (Experimental Chemoradiotherapy) | -46.45 | 22.99 | Not reported | Not reported | Not reported |
|---|
ΔSUVpeak (Alive - No progression)
Analysis denominator · Participants
| Group | Source count |
|---|
| Both Arms | 19 |
|---|
| Arm I (Standard Chemoradiotherapy) | 9 |
|---|
| Arm II (Experimental Chemoradiotherapy) | 10 |
|---|
Values in percent change · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Both Arms | -44.36 | 26.77 | Not reported | Not reported | Not reported |
|---|
| Arm I (Standard Chemoradiotherapy) | -40.46 | 31.93 | Not reported | Not reported | Not reported |
|---|
| Arm II (Experimental Chemoradiotherapy) | -47.87 | 22.31 | Not reported | Not reported | Not reported |
|---|
ΔSUVpeak (Progression/Deceased)
Analysis denominator · Participants
| Group | Source count |
|---|
| Both Arms | 88 |
|---|
| Arm I (Standard Chemoradiotherapy) | 27 |
|---|
| Arm II (Experimental Chemoradiotherapy) | 61 |
|---|
Values in percent change · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Both Arms | -38.82 | 40.68 | Not reported | Not reported | Not reported |
|---|
| Arm I (Standard Chemoradiotherapy) | -37.44 | 31.97 | Not reported | Not reported | Not reported |
|---|
| Arm II (Experimental Chemoradiotherapy) | -39.44 | 44.21 | Not reported | Not reported | Not reported |
|---|
ΔSUVpeak (Alive - Lung Cancer progression/death)
Analysis denominator · Participants
| Group | Source count |
|---|
| Both Arms | 48 |
|---|
| Arm I (Standard Chemoradiotherapy) | 16 |
|---|
| Arm II (Experimental Chemoradiotherapy) | 32 |
|---|
Values in percent change · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Both Arms | -39.15 | 49.02 | Not reported | Not reported | Not reported |
|---|
| Arm I (Standard Chemoradiotherapy) | -42.35 | 25.90 | Not reported | Not reported | Not reported |
|---|
| Arm II (Experimental Chemoradiotherapy) | -37.55 | 57.54 | Not reported | Not reported | Not reported |
|---|
ΔSUVpeak (Lung Cancer progression/death)
Analysis denominator · Participants
| Group | Source count |
|---|
| Both Arms | 59 |
|---|
| Arm I (Standard Chemoradiotherapy) | 20 |
|---|
| Arm II (Experimental Chemoradiotherapy) | 39 |
|---|
Values in percent change · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Both Arms | -40.34 | 27.65 | Not reported | Not reported | Not reported |
|---|
| Arm I (Standard Chemoradiotherapy) | -34.88 | 35.71 | Not reported | Not reported | Not reported |
|---|
| Arm II (Experimental Chemoradiotherapy) | -43.15 | 22.49 | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 53.23
- value
- -34.71
- group Id
- OG001
- spread
- 27.07
- value
- -44.13
- group Id
- OG002
- spread
- 63.71
- value
- -29.21
- denoms
- counts
- group Id
- OG000
- value
- 38
- group Id
- OG001
- value
- 14
- group Id
- OG002
- value
- 24
- units
- Participants
- title
- ΔSUVpeak (Alive)
- categories
- measurements
- group Id
- OG000
- spread
- 27.37
- value
- -42.62
- group Id
- OG001
- spread
- 34.13
- value
- -34.43
- group Id
- OG002
- spread
- 22.99
- value
- -46.45
- denoms
- counts
- group Id
- OG000
- value
- 69
- group Id
- OG001
- value
- 22
- group Id
- OG002
- value
- 47
- units
- Participants
- title
- ΔSUVpeak (Deceased)
- categories
- measurements
- group Id
- OG000
- spread
- 26.77
- value
- -44.36
- group Id
- OG001
- spread
- 31.93
- value
- -40.46
- group Id
- OG002
- spread
- 22.31
- value
- -47.87
- denoms
- counts
- group Id
- OG000
- value
- 19
- group Id
- OG001
- value
- 9
- group Id
- OG002
- value
- 10
- units
- Participants
- title
- ΔSUVpeak (Alive - No progression)
- categories
- measurements
- group Id
- OG000
- spread
- 40.68
- value
- -38.82
- group Id
- OG001
- spread
- 31.97
- value
- -37.44
- group Id
- OG002
- spread
- 44.21
- value
- -39.44
- denoms
- counts
- group Id
- OG000
- value
- 88
- group Id
- OG001
- value
- 27
- group Id
- OG002
- value
- 61
- units
- Participants
- title
- ΔSUVpeak (Progression/Deceased)
- categories
- measurements
- group Id
- OG000
- spread
- 49.02
- value
- -39.15
- group Id
- OG001
- spread
- 25.90
- value
- -42.35
- group Id
- OG002
- spread
- 57.54
- value
- -37.55
- denoms
- counts
- group Id
- OG000
- value
- 48
- group Id
- OG001
- value
- 16
- group Id
- OG002
- value
- 32
- units
- Participants
- title
- ΔSUVpeak (Alive - Lung Cancer progression/death)
- categories
- measurements
- group Id
- OG000
- spread
- 27.65
- value
- -40.34
- group Id
- OG001
- spread
- 35.71
- value
- -34.88
- group Id
- OG002
- spread
- 22.49
- value
- -43.15
- denoms
- counts
- group Id
- OG000
- value
- 59
- group Id
- OG001
- value
- 20
- group Id
- OG002
- value
- 39
- units
- Participants
- title
- ΔSUVpeak (Lung Cancer progression/death)
- denoms
- counts
- group Id
- OG000
- value
- 107
- group Id
- OG001
- value
- 36
- group Id
- OG002
- value
- 71
- units
- Participants
- description
- ΔSUVpeak will be measured as 100\* (SUVpeak Mid-treatment - SUVpeak baseline)/(SUVpeak baseline) All survival measures will be measured in days from registration up to 5 years.
- dispersion Type
- Standard Deviation
- groups
- description
- Patients undergo chemoradiotherapy as defined for the arm of the study to which they were randomized.
18F-Fluoromisonidazole: Undergo FMISO PET/CT prior to therapy for patients enrolling at institutions participating in the FMISO correlative study
- id
- OG000
- title
- Both Arms
- description
- Patients undergo standard radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FMISO-PET imaging at baseline
18F-Fluoromisonidazole: Undergo FMISO PET/CT prior to therapy for patients enrolling at institutions participating in the FMISO correlative study
Carboplatin: Given IV
External Beam Radiation Therapy: Undergo radiotherapy
- id
- OG001
- title
- Arm I (Standard Chemoradiotherapy)
- description
- Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.
18F-Fluoromisonidazole: Participants enrolled at institutions participating in the FMISO correlative study undergo FMISO-PET prior to treatment
Carboplatin: Given IV
Computed Tomography: Undergo FDG PET/CT
Computed Tomography: Undergo FMISO PET/CT (Correlative studies)
Fludeoxyglucose F-18: Undergo FDG PET/CT
Image-Guided Adaptive Radiation Therapy: Undergo individualized adaptive radiotherapy
Laboratory Biomarker Analysis: Correlative studies
Paclitaxel: Given IV
Positron Emission Tomography: Undergo FDG PET/CT
Positron Emission Tomography: Undergo FMISO PET/CT (Correlative studies)
- id
- OG002
- title
- Arm II (Experimental Chemoradiotherapy)
- param Type
- MEAN
- population Description
- As a predictive marker, relative SUVpeak is reported by survival status in each survival category. For example, Relative ΔSUVpeak is reported separately for the 38 participants who were alive at the 5 year milestone and for the 69 patients who were not.
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- ΔSUVpeak Prediction of Overall Survival, Progression Free Survival, and Lung Cancer Cause-specific Survival (ECOG-ACRIN)
- type
- SECONDARY
- unit Of Measure
- percent change
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle